Ajeeta Dash

6PUBLICATIONS
39CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersMedical mycologyGene and molecular therapyBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.

Ola Landgren, Thomas J Prior, Tara Masterson

|Jan 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.

Wee-Joo Chng, Sagar Lonial, Gareth J Morgan

|Sep 21, 2022
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.

Bruno Paiva, Irene Manrique, Meletios A Dimopoulos

|Jul 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Kenneth C Anderson, Daniel Auclair, Stacey J Adam

|May 01, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.

Ajeeta B Dash, Jacob Zhang, Lei Shen

|Jan 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Ronan T Swords, Steven Coutre, Michael B Maris

Pageof 1

Frequent Collaborators

2 joint publications

Saran Vardhanabhuti

2 joint publications

Ola Landgren

2 joint publications

Francesca Gay

2 joint publications

Alessandra Di Bacco